Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of ...

test offerings to include MET IHC testing using the VENTANA® MET (SP44) RxDx assay, now available as an add-on to comprehensive genomic profiling (CGP) test orders for patients with non-squamous ...

The global immunohistochemistry (IHC) market is experiencing steady growth, with a compound annual growth rate (CAGR) of ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize ... United States that has historically and is currently offering the [MET IHC] assay for ...

Caris is addressing these challenges by leveraging the power of MET IHC testing, which evaluates the expression of the MET protein in cancer cells. This protein is known to play a crucial role in ...

Tempus will notify physicians of patients who are identified by the algorithm as more likely to be HER2 positive, so that they can consider ordering confirmatory IHC testing from their laboratory ...

Foundation Medicine’s IHC test offerings include: MET IHC testing, which helps identify patients with locally advanced or metastatic non-squamous NSCLC who exhibit high c-Met protein ...